Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | CCR8 | P51685 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705189 | 0.84 | ADORA2A (0.37) | CCR1CCR5CCR8KCNH2HRH4 | |
| SCHEMBL18779069 | 0.82 | CCR1 (0.57) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL18791200 | 0.81 | CCR1 (0.33) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL18791475 | 0.81 | PAK4 (0.37) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL13706081 | 0.81 | CCR1 (0.52) | CCR1CCR5CCR8KCNH2HRH4 | |
| SCHEMBL24109755 | 0.78 | PDE4A (0.32) | CCR1CCR5CCR8KCNH2HRH4 | |
| SCHEMBL10058360 | 0.75 | KCNH2 (0.32) | KCNH2HRH4HRH3 | |
| SCHEMBL25054661 | 0.75 | CLK1 (0.45) | CCR1CCR5CCR8 | |
| SCHEMBL21377459 | 0.74 | CCR1 (0.62) | CCR1CCR5CCR8PSMD14COPS5 | |
| SCHEMBL13707462 | 0.73 | CCR1 (0.70) | CCR1CCR5CCR8KCNH2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-20170312277-A1 | Compounds for Treatment of Fibrosis Diseases | CUREGENIX, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9744169-B2 | Compounds for treatment of fibrosis diseases | CUREGENIX, INC. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX, INC. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX, INC. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-9556144-B2 | Compound as WNT signaling inhibitor, composition, and use thereof | CUREGENIX, INC. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160000780-A1 | Compounds for Treatment of Cancer | CUREGENIX, INC. (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160000779-A1 | Compounds for Treatment of Fibrosis Diseases | CUREGENIX, INC. (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20150119387-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | CUREGENIX INC. (CN) | 2015-04-30 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000779-A1 | Compounds for Treatment of Fibrosis Diseases | WNT1, WNT3A, WNT3 | CCR1 82/4885CCR5 208/4885CCR8 225/4885 |
| US-20170088549-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | CCR1 2100/4885CCR5 2726/4885CCR8 1996/4885 |
| US-20170073344-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | WNT1, WNT3A, SFRP1 | CCR1 3869/4885CCR5 2869/4885CCR8 4125/4885 |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | CCR1 1903/4885CCR5 2444/4885CCR8 3943/4885 |
| US-20170312277-A1 | Compounds for Treatment of Fibrosis Diseases | WNT1, SFRP1, WNT3 | CCR1 442/4885CCR5 350/4885CCR8 697/4885 |
| US-20150119387-A1 | Compound as WNT Signaling Inhibitor, Composition, and Use Thereof | WNT1, WNT3A, SFRP1 | CCR1 3831/4885CCR5 2939/4885CCR8 4045/4885 |
| US-20160000780-A1 | Compounds for Treatment of Cancer | WNT1, CTNNB1, WNT3 | CCR1 3570/4885CCR5 2652/4885CCR8 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.